95 related articles for article (PubMed ID: 15980618)
1. FHD: an index to evaluate drug elimination by hemodialysis.
Launay-Vacher V; Izzedine H; Baumelou A; Deray G
Am J Nephrol; 2005; 25(4):342-51. PubMed ID: 15980618
[TBL] [Abstract][Full Text] [Related]
2. Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients.
Ahuja TS; Niaz N; Velasco A; Watts B; Paar D
Clin Nephrol; 1999 Jan; 51(1):40-4. PubMed ID: 9988145
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of polyneuropathy severity in chronic renal failure patients on continuous ambulatory peritoneal dialysis or on maintenance hemodialysis].
Janda K; Stompór T; Gryz E; Szczudlik A; Drozdz M; Kraśniak A; Sułowicz W
Przegl Lek; 2007; 64(6):423-30. PubMed ID: 18159852
[TBL] [Abstract][Full Text] [Related]
4. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
5. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of phosphorus during hemodialysis and the calculation of its effective dialysis clearance.
Schück O; Kaslikov J
Clin Nephrol; 1997 Jun; 47(6):379-83. PubMed ID: 9202868
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
8. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
Don BR; Spin G; Nestorov I; Hutmacher M; Rose A; Kaysen GA
J Pharm Pharmacol; 2005 Nov; 57(11):1407-13. PubMed ID: 16259772
[TBL] [Abstract][Full Text] [Related]
10. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation.
Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Manini P; Andreoli R; Cabassi A
Nephrol Dial Transplant; 2006 May; 21(5):1402-6. PubMed ID: 16504979
[TBL] [Abstract][Full Text] [Related]
11. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B
Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549
[TBL] [Abstract][Full Text] [Related]
12. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. [Late nephrology referral influences on morbidity and mortality of hemodialysis patients. A provincial study].
Peña JM; Logroño JM; Pernaute R; Laviades C; Virto R; Vicente de Vera C
Nefrologia; 2006; 26(1):84-97. PubMed ID: 16649429
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
[TBL] [Abstract][Full Text] [Related]
16. Minutes to recovery after a hemodialysis session: a simple health-related quality of life question that is reliable, valid, and sensitive to change.
Lindsay RM; Heidenheim PA; Nesrallah G; Garg AX; Suri R;
Clin J Am Soc Nephrol; 2006 Sep; 1(5):952-9. PubMed ID: 17699312
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of vitamin E metabolites in the blood of renal failure patients.
Galli F; Floridi AG; Floridi A; Buoncristiani U
Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory, degenerative and vascular lesions in long-term dialysed patients.
Vrabie CD; Petrescu A; Waller M; Cojocaru M; Ciocâlteu A; Dina I
Rom J Intern Med; 2009; 47(2):149-59. PubMed ID: 20067165
[TBL] [Abstract][Full Text] [Related]
19. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
